Results 201 to 210 of about 75,341 (263)

Insomnia Subtypes in Clinical Population According to the Insomnia Type Questionnaire (ITQ): A Multi‐Centre Study in Spanish Sleep Clinics

Journal of Sleep Research, Volume 35, Issue 1, February 2026.
ABSTRACT The lack of robust subtyping for insomnia disorder (ID) led to its current classification as a uniform condition. A novel approach to subtyping ID developed a new tool, the insomnia type questionnaire (ITQ). Our research aimed to assess whether the ID subtypes identified in the general population could also be found in ID patients referred to ...
Francesca Canellas, Manuel de Entrambasaguas, Odile Romero, Ainhoa Álvarez, Rybel Wix, Francisco Javier Puertas, Jesús Pujol, Guillem Frontera   +7 more
wiley   +1 more source

Metabolic Problems Among People With Treatment-Resistant Schizophrenia are Not Unique to Clozapine. [PDF]

J Clin Psychopharmacol
John AP, Prajapati H, Dragovic M.
europepmc   +1 more source

Biochemical and Physiological Effects of Galanin in Health and Disease

The FASEB Journal, Volume 40, Issue 2, 31 January 2026.
Galanin is a biologically active neuropeptide hormone that mediates its effects through three galanin receptors. Galanin signaling induces changes in glucose homeostasis amongst others and plays a dynamic role in the physiological health of many organ systems.
Patrick Mireles, Yubo Wang, Kathryn Rhodes, Sharon DeMorrow   +3 more
wiley   +1 more source

Managing treatment-resistant schizophrenia following clozapine cessation: a case report of xanomeline-trospium and olanzapine combination therapy. [PDF]

Front Psychiatry
Went NS, Alonso JD, Rigunay RR, Hershberger J, You XX.   +4 more
europepmc   +1 more source

Evaluating the Role of Clozapine in Treatment-Resistant Schizophrenia: A Narrative Synthesis of Clinical, Economic, and Quality-of-Life Outcomes. [PDF]

Neuropsychiatr Dis Treat
Erlianti K, Alfaqeeh M, Puspitasari IM, Purba FD, Suwantika AA.   +4 more
europepmc   +1 more source